EE219 Lorlatinib as a First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer: A Cost-Effectiveness Analysis in Greece
Abstract
Authors
G. Gourzoulidis O. Zisimopoulou A. Liavas C. Tzanetakos